Free shipping on all orders over $ 500

OSU-T315

Cat. No. M13754
OSU-T315 Structure
Size Price Availability Quantity
5mg USD 270  USD270 In stock
10mg USD 450  USD450 In stock
25mg USD 790  USD790 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.

Chemical Information
Molecular Weight 533.59
CAS Number 2070015-22-2
Solubility (25°C) DMSO ≥ 150 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Zhihui Li, et al. Cell Biol Int. OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells

[2] Haifeng Chen, et al. Bioengineered. GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway

[3] Kristien Van Belle, et al. J Immunol Res. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics

[4] M E Mercado-Pimentel, et al. Austin J Med Oncol. The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation

[5] Ta-Ming Liu, et al. Blood. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Related Integrin Products
HSDVHK-NH2

HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).

LDV

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC.

Cyclo(RADfK)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

Obtustatin

Obtustatin is a non-RGD disintegrin of 41 residues.

Integrin Binding Peptide

Integrin Binding Peptide is derived by fibronectin.

  Catalog
Abmole Inhibitor Catalog




Keywords: OSU-T315 supplier, Integrin, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.